AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: AstraZeneca is conducting a clinical study titled An Open-label, Fixed-sequence, Three-part Study to Assess the Effect of AZD5004 on the Pharmacokinetics of Rosuvastatin, Atorvastatin, Simvastatin, Repaglinide and to Assess the Effect of Erythromycin on AZD5004 in Healthy Participants. The study aims to evaluate how AZD5004 affects the pharmacokinetics of several drugs in healthy individuals, which could have significant implications for drug interactions and patient safety.
Intervention/Treatment: The study tests AZD5004, a drug administered in combination with rosuvastatin, atorvastatin, simvastatin, repaglinide, and erythromycin. The purpose is to understand the pharmacokinetic interactions between these drugs when co-administered with AZD5004.
Study Design: This is a Phase I, open-label, non-randomized study with a factorial intervention model. It involves no masking and focuses on treatment. The study is divided into three independent parts, each assessing different drug interactions.
Study Timeline: The study began on May 6, 2025, with its last update on August 4, 2025. These dates are crucial as they mark the study’s progression and the latest information available to stakeholders.
Market Implications: This study could influence AstraZeneca’s stock performance by providing insights into the safety and efficacy of AZD5004, potentially affecting investor sentiment. The results may also impact competitive dynamics in the pharmaceutical industry, particularly in the area of drug interactions.
The study is ongoing, with further details available on the ClinicalTrials portal.